A phase II study of temsirolimus in previously treated advanced hepatocellular carcinoma (HCC)
| Autor: | Jasgit C. Sachdev, Shannon Gulla, Ronald I Korn, Ronald G. Newbold, Matthew P. Smeltzer, Ahmed Y. Javed, Raymond U. Osarogiagbon, Alva Bowen Weir |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Sorafenib
Cancer Research Pathology medicine.medical_specialty business.industry Phases of clinical research medicine.disease Discovery and development of mTOR inhibitors Preclinical data digestive system diseases Temsirolimus Oncology Downregulation and upregulation Hepatocellular carcinoma Cancer research medicine Previously treated business neoplasms medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 32:4098-4098 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2014.32.15_suppl.4098 |
| Popis: | 4098 Background: After Sorafenib failure,there is no effective systemic therapy for advanced HCC. Preclinical data show upregulated mTOR signaling in HCC. We tested the IV mTOR inhibitor (i), Temsi... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|